Regeneron Pharmaceuticals Inc. ($REGN) Stock Forecast: Down 3.1% Today

What is Regeneron Pharmaceuticals Inc.?

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a biotechnology company recognized for its innovative treatments across various therapeutic areas like ophthalmology, oncology, and rare diseases. The stock demonstrated significant bearish movement today.

Why is Regeneron Pharmaceuticals Inc. going down?

REGN stock is down 3.1% on Apr 24, 2026 15:00

• A decrease in the price target for REGN to $913 from $921 by Bernstein SocGen, while maintaining an Outperform rating, potentially influenced the bearish trend, hinting at a downside.
• Despite M&T Bank Corp increasing its stake by 193.9% and positive developments including FDA approval of a gene therapy, concerns about near-term revenue limitations seemed to outweigh the positive news, contributing to the bearish sentiment.
• Although analysis indicated REGN might be undervalued and positive factors like tariff relief and dividend increment were present, the prevailing market sentiment eclipsed these, resulting in the bearish movement.
• The reduction of stake by China Universal Asset Management Co. Ltd. by 7.5%, contrasted with positive developments and an earnings beat, likely intensified selling pressure on the stock, further fueling the bearish movement.

REGN Price Chart

REGN Technical Analysis

REGN News

Bernstein SocGen lowers Regeneron stock price target to $913

Bernstein SocGen Group has reduced its price target for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to $913 from $921, while maintaining an Outperform rating. The stock is currently trading at $766.02, significantly below the updated target. Despite the lowered target, analysts still suggest the stock is undervalued according to InvestingPro, though 8 analysts have revised earnings downwards for the upcoming period.

https://www.investing.com/news/analyst-ratings/bernstein-socgen-lowers-regeneron-stock-price-target-to-913-93CH-4635847

How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story

Telix Pharmaceuticals has

https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-regeneron-tie-up-and-phase-3-pipeline-advances-at-telix/amp

M&T Bank Corp Buys 10,350 Shares of Regeneron Pharmaceuticals, Inc. $REGN

M&T Bank Corp significantly increased its stake in Regeneron Pharmaceuticals Inc. by 193.9%, acquiring an additional 10,350 shares to hold a total of 15,689 shares valued at $12.11 million. This increase follows positive developments for Regeneron, including FDA approval of a gene therapy and favorable analyst upgrades, despite some potential near-term revenue limitations due to providing the therapy for free to eligible U.S. patients. The company also reported strong Q4 EPS, raised its dividend, and maintains a "Moderate Buy" consensus rating among analysts.

https://www.marketbeat.com/instant-alerts/filing-mt-bank-corp-buys-10350-shares-of-regeneron-pharmaceuticals-inc-regn-2026-04-24/

Is Regeneron Pharmaceuticals (REGN) Still Attractive After Recent Share Price Strength?

This article analyzes Regeneron Pharmaceuticals (REGN) at its current share price of US$766.02 using a 6-point valuation framework. It employs a Discounted Cash Flow (DCF) model and P/E ratio analysis, both suggesting the stock is undervalued. The article also presents "Bull" and "Bear" narratives with differing fair value estimates (US$873.78 and US$730.00 respectively) to help investors assess the company's future prospects.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/is-regeneron-pharmaceuticals-regn-still-attractive-after-rec-1

China Universal Asset Management Co. Ltd. Has $15.25 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

China Universal Asset Management Co. Ltd. reduced its stake in Regeneron Pharmaceuticals (REGN) by 7.5% in the fourth quarter, now holding 19,753 shares valued at $15.25 million, making it their 19th largest holding. Despite this reduction and recent insider selling, Regeneron Pharmaceuticals has several positive catalysts, including FDA approval of gene therapy Otarmeni, tariff relief, and a dividend increase, contributing to a consensus "Moderate Buy" rating from analysts. The company also recently reported an earnings beat, with reported EPS of $11.44 exceeding the consensus estimate of $10.74.

https://www.marketbeat.com/instant-alerts/filing-china-universal-asset-management-co-ltd-has-1525-million-holdings-in-regeneron-pharmaceuticals-inc-regn-2026-04-24/

Trending Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Packaging Corporation of America ($PKG) Stock Forecast: Up 3.1% Today

AvalonBay Communities Inc. ($AVB) Stock Forecast: Up 5.1% Today

Allegion plc ($ALLE) Stock Forecast: Down 7.4% Today

Franklin Resources Inc. ($BEN) Stock Forecast: Up 5.5% Today

Centene Corporation ($CNC) Stock Forecast: Up 15.3% Today

PACCAR Inc. ($PCAR) Stock Forecast: Down 6.5% Today

Regeneron Pharmaceuticals Inc. Price History

30.04.2025 - REGN Stock was down 18.4%

• Mixed results from late-stage COPD studies conducted by Regeneron and SNY could have led to investor uncertainty and a sell-off of REGN shares.
• Meeting the primary endpoint in one trial but missing in another may have raised concerns about the drug's overall effectiveness and potential market approval.
• The uncertainty surrounding future plans for itepekimab in treating COPD could have contributed to the bearish market movement of REGN today.

18.08.2025 - REGN Stock was down 0.1%

• Despite promising results from a Phase 3 study on Garetosmab demonstrating a notable decrease in new bone lesions and favorable tolerability, the stock's decline may be linked to factors like general market sentiment or profit-taking.
• Concerns among investors may stem from the anticipation of a Wall Street trader's upcoming strategy unveiling, leading to apprehension and selling pressure on REGN shares.
• The drop in stock value may also reflect broader industry patterns or external market conditions affecting biotech stocks, resulting in a retreat in Regeneron's stock price.

01.07.2025 - REGN Stock was down 1.9%

• The stock had a bearish movement as analysts are expecting lower Q2 earnings compared to the year-ago period.
• The anticipated decrease in quarterly earnings to $8.43 per share, down from $11.56 per share, likely contributed to the bearish trend.
• Despite the long-term outperformance of Regeneron Pharmaceuticals, short-term concerns about earnings may have led to the negative market movement.
• Investors may be reacting to the revised forecasts ahead of the earnings call, causing a dip in the stock price.

13.00.2026 - REGN Stock was down 5.4%

• A notable investor, PKO Investment Management Joint Stock Co, reduced its stake in Regeneron Pharmaceuticals by 40.4%, potentially sparking concerns among investors and contributing to the stock sell-off.
• The focus on AbbVie's MFN drug pricing agreement and US R&D commitment may have diverted attention from Regeneron, impacting its stock negatively.
• Raymond James increased Regeneron's price target to $820 from $800, displaying long-term confidence in the company, although short-term profit-taking behavior could have influenced the immediate market reaction.
• Strong financial performance and favorable analyst recommendations support an optimistic outlook on Regeneron, suggesting that the recent bearish movement might be a temporary decline amidst overall positive sentiment towards the company.

28.09.2025 - REGN Stock was up 6.5%

• The upcoming Q3 earnings report for Regeneron is expected to focus on the performance of Dupixent and Eylea sales.
• Investors are optimistic about the potential of higher profits from Dupixent offsetting any decline in Eylea sales.
• The strong uptake of Eylea HD amid competition is also a key factor driving positive sentiment towards REGN stock.
• Overall, the market seems to be reacting positively to the potential growth prospects highlighted in the upcoming earnings report, leading to the bullish movement in REGN stock.

02.11.2025 - REGN Stock was down 5.7%

• The bearish movement in REGN's stock today can be attributed to Quadrant Capital Group LLC selling 688 shares, reducing its stake in the company by 25.6%. This sell-off might have created a negative sentiment among investors, leading to a decline in the stock price.
• Despite surpassing earnings expectations and maintaining strong profitability, REGN's stock underperformed on a day when the overall market, as represented by the S&P 500 Index and Dow Jones Industrial Average, also experienced losses. This broader market trend could have contributed to the downward pressure on REGN's stock.
• The partnership with Tessera Therapeutics to develop a gene-editing therapy for a rare disorder highlights REGN's commitment to innovation. However, heightened competition and potential regulatory delays mentioned in recent sources may have raised concerns among investors, impacting the stock price negatively.
• The overall positive outlook on REGN, with analysts rating it a "Moderate Buy" and the company announcing a quarterly dividend, suggests that the bearish movement today could be a short-term correction amidst a backdrop of long-term growth potential.

05.01.2026 - REGN Stock was down 0.4%

• The bearish movement in Regeneron's stock could be attributed to the overall negative sentiment surrounding the biotech sector, as highlighted by concerns over gene therapy safety issues at Sarepta Therapeutics and the competitive landscape.
• The selling of Ocular Therapeutix stock by its COO amidst a significant price drop and concerns about overvaluation in the sector may have added to the bearish pressure on biotech stocks, including Regeneron.
• Comments on Moderna and preference for other pharma and biotech names, particularly mentioning Regeneron as a more favorable option, could have influenced investor sentiment and contributed to the downward movement in Regeneron's stock price.
• The overall market perception of biotech companies may have led to profit-taking and a shift in investment focus away from companies like Regeneron, impacting its stock performance negatively.

24.03.2026 - REGN Stock was down 3.1%

• A decrease in the price target for REGN to $913 from $921 by Bernstein SocGen, while maintaining an Outperform rating, potentially influenced the bearish trend, hinting at a downside.
• Despite M&T Bank Corp increasing its stake by 193.9% and positive developments including FDA approval of a gene therapy, concerns about near-term revenue limitations seemed to outweigh the positive news, contributing to the bearish sentiment.
• Although analysis indicated REGN might be undervalued and positive factors like tariff relief and dividend increment were present, the prevailing market sentiment eclipsed these, resulting in the bearish movement.
• The reduction of stake by China Universal Asset Management Co. Ltd. by 7.5%, contrasted with positive developments and an earnings beat, likely intensified selling pressure on the stock, further fueling the bearish movement.

11.11.2025 - REGN Stock was up 5.6%

• Intact Investment Management Inc. significantly increasing its stake in REGN indicates growing confidence in the company's future prospects, potentially contributing to the bullish movement.
• Positive early data on Regeneron's Lynozyfic monotherapy for multiple myeloma patients showcases the company's promising developments in the oncology sector, boosting investor sentiment.
• Increasing the price target for REGN reflects optimism in the company's performance, aligning with the overall bullish trend in the market.
• The strong performance of AbbVie and Genmab's Epkinly at the ASH Annual Meeting may have positively influenced the biotech sector as a whole, indirectly benefiting companies like Regeneron.

10.05.2025 - REGN Stock was up 5.1%

• The bullish movement in REGN stock today can be attributed to the positive news of expanding its pipeline through a strategic deal in the obesity drug market. Investors seem optimistic about the company's efforts to address challenges in its existing portfolio and capitalize on new opportunities for growth, leading to increased confidence and buying interest in the stock.

07.00.2026 - REGN Stock was up 5.2%

• Regeneron's stock rose by 2.9% following an upgrade in its rating to 'Buy' by Bank of America Securities, which also raised the price target to $860. A similar upgrade came from Citi, setting a price target of $900. These positive evaluations by analysts boosted confidence among investors regarding the company's future outlook.
• Merit Financial Group LLC notably increased its stake in Regeneron during the third quarter, indicating strong financial performance that surpassed analyst projections. This move further contributed to the overall positive trend in the company's stock value.
• The projected growth in the Diabetic Macular Edema (DME) market, where Regeneron holds a significant position, also added to the favorable prospects for the company. Forecasts suggest that the market for DME could reach US$ 7.44 billion by 2033, driven by advancements in retinal therapies. This anticipated growth aligns well with Regeneron's standing in the industry.

01.09.2025 - REGN Stock was up 5.3%

• The momentum could be linked to the FDA's approval for the label extension of REGN's cholesterol drug Evkeeza, permitting its usage in children as young as one suffering from severe familial hypercholesterolemia.
• The FDA's endorsement for expanding the utilization of Regeneron's Evkeeza to infants with a rare cholesterol disorder may have instilled confidence in investors regarding the company's pipeline and prospective revenue.
• Anticipation surrounding Regeneron's forthcoming third-quarter financial and operating results announcement might also be fostering optimism among investors, who foresee strong performance and growth opportunities.